RESUMEN
INTRODUCTION: Pulmonary alveolar proteinosis related to mutations in the methionine tRNA synthetase (MARS1) gene is a severe, early-onset disease that results in death before the age of 2â years in one-third of patients. It is associated with a liver disease, growth failure and systemic inflammation. As methionine supplementation in yeast models restored normal enzymatic activity of the synthetase, we studied the tolerance, safety and efficacy of daily oral methionine supplementation in patients with severe and early disease. METHODS: Four patients received methionine supplementation and were followed for respiratory, hepatic, growth and inflammation-related outcomes. Their course was compared to those of historical controls. Reactive oxygen species production by patient monocytes before and after methionine supplementation was also studied. RESULTS: Methionine supplementation was associated with respiratory improvement, clearance of the extracellular lipoproteinaceous material and discontinuation of whole-lung lavage in all patients. The three patients who required oxygen or noninvasive ventilation could be weaned off within 60â days. In addition, liver dysfunction, inflammation and growth delay improved or resolved. At a cellular level, methionine supplementation normalised the production of reactive oxygen species by peripheral monocytes. CONCLUSION: Methionine supplementation was associated with important improvements in children with pulmonary alveolar proteinosis related to mutations in the MARS1 gene. This study paves the way for similar strategies for other tRNA synthetase deficiencies.
Asunto(s)
Suplementos Dietéticos , Metionina , Insuficiencia Multiorgánica , Proteinosis Alveolar Pulmonar , Lavado Broncoalveolar/métodos , Niño , Preescolar , Humanos , Inflamación , Metionina/uso terapéutico , Metionina-ARNt Ligasa/genética , Insuficiencia Multiorgánica/tratamiento farmacológico , Proteinosis Alveolar Pulmonar/tratamiento farmacológico , Proteinosis Alveolar Pulmonar/genética , Especies Reactivas de OxígenoAsunto(s)
Inmunidad Activa/efectos de los fármacos , Lupus Eritematoso Sistémico/inmunología , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/inmunología , Adulto , Anciano , Femenino , Humanos , Lupus Eritematoso Sistémico/microbiología , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
BACKGROUND AND PURPOSE: Neutrophil overstimulation plays a crucial role in tissue damage during severe infections. Because pathogen-derived neuraminidase (NEU) stimulates neutrophils, we investigated whether host NEU can be targeted to regulate the neutrophil dysregulation observed in severe infections. EXPERIMENTAL APPROACH: The effects of NEU inhibitors on lipopolysaccharide (LPS)-stimulated neutrophils from healthy donors or COVID-19 patients were determined by evaluating the shedding of surface sialic acids, cell activation, and reactive oxygen species (ROS) production. Re-analysis of single-cell RNA sequencing of respiratory tract samples from COVID-19 patients also was carried out. The effects of oseltamivir on sepsis and betacoronavirus-induced acute lung injury were evaluated in murine models. KEY RESULTS: Oseltamivir and zanamivir constrained host NEU activity, surface sialic acid release, cell activation, and ROS production by LPS-activated human neutrophils. Mechanistically, LPS increased the interaction of NEU1 with matrix metalloproteinase 9 (MMP-9). Inhibition of MMP-9 prevented LPS-induced NEU activity and neutrophil response. In vivo, treatment with oseltamivir fine-tuned neutrophil migration and improved infection control as well as host survival in peritonitis and pneumonia sepsis. NEU1 also is highly expressed in neutrophils from COVID-19 patients, and treatment of whole-blood samples from these patients with either oseltamivir or zanamivir reduced neutrophil overactivation. Oseltamivir treatment of intranasally infected mice with the mouse hepatitis coronavirus 3 (MHV-3) decreased lung neutrophil infiltration, viral load, and tissue damage. CONCLUSION AND IMPLICATIONS: These findings suggest that interplay of NEU1-MMP-9 induces neutrophil overactivation. In vivo, NEU may serve as a host-directed target to dampen neutrophil dysfunction during severe infections.
Asunto(s)
COVID-19 , Sepsis , Humanos , Ratones , Animales , Oseltamivir/efectos adversos , Zanamivir/efectos adversos , Neuraminidasa/metabolismo , Neuraminidasa/farmacología , Neutrófilos , Metaloproteinasa 9 de la Matriz/metabolismo , Especies Reactivas de Oxígeno , Lipopolisacáridos/farmacología , Sepsis/inducido químicamenteAsunto(s)
Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/cirugía , Trasplante de Pulmón/efectos adversos , Complicaciones Posoperatorias , Proteinosis Alveolar Pulmonar/complicaciones , Anciano , Lavado Broncoalveolar , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Humanos , Pulmón/inmunología , Pulmón/cirugía , Masculino , Persona de Mediana Edad , Proteinosis Alveolar Pulmonar/patología , Surfactantes Pulmonares , Transducción de SeñalRESUMEN
A 75-year-old men is adressed in rheumatology for lower back pain, asthenia, and recent weight loss. Myeloma is suspected. Anemia, hyperproteinemia as well as a monoclonal IgG kappa with serum protein immunofixation are discovered. The diagnosis is confirmed by the myelogram with 14% of medullar plasmocytes. Osteolytic lesions are also found on the scanner.
Un homme de 75 ans a consulté en rhumatologie pour des douleurs lombaires, une asthénie et une perte de poids d'apparition récente. Un myélome est suspecté. Une anémie, une hyperprotidémie ainsi qu'une IgG kappa monoclonale à l'immunofixation des protéines sériques sont retrouvés. Le diagnostic est confirmé par le myélogramme qui décompte 14 % de plasmocytes. Des lésions ostéolytiques sont également mises en évidence au scanner.
Asunto(s)
Dolor de la Región Lumbar , Mieloma Múltiple , Masculino , Humanos , Anciano , Dolor de la Región Lumbar/diagnóstico , Dolor de la Región Lumbar/etiología , Mieloma Múltiple/diagnóstico , Proteínas Sanguíneas , Pérdida de PesoRESUMEN
Neutrophil overstimulation plays a crucial role in tissue damage during severe infections. Neuraminidase (NEU)-mediated cleavage of surface sialic acid has been demonstrated to regulate leukocyte responses. Here, we report that antiviral NEU inhibitors constrain host NEU activity, surface sialic acid release, ROS production, and NETs released by microbial-activated human neutrophils. In vivo, treatment with Oseltamivir results in infection control and host survival in peritonitis and pneumonia models of sepsis. Single-cell RNA sequencing re-analysis of publicly data sets of respiratory tract samples from critical COVID-19 patients revealed an overexpression of NEU1 in infiltrated neutrophils. Moreover, Oseltamivir or Zanamivir treatment of whole blood cells from severe COVID-19 patients reduces host NEU-mediated shedding of cell surface sialic acid and neutrophil overactivation. These findings suggest that neuraminidase inhibitors can serve as host-directed interventions to dampen neutrophil dysfunction in severe infections.
RESUMEN
Anaphylaxis is a systemic acute hypersensitivity reaction that is considered to depend on allergen-specific immunoglobulin E (IgE) antibodies and histamine release by mast cells and basophils. Nevertheless, allergen-specific IgG antibodies have been proposed to contribute when the allergen is an abundant circulating large molecule, e.g., after infusions of therapeutic antibodies or dextran. Data from animal models demonstrate a pathway involving platelet-activating factor (PAF) release by monocytes/macrophages and neutrophils activated via their Fc gamma receptors (FcγRs). We hypothesized that such a pathway may also apply to small drugs and could be responsible for non-IgE-mediated anaphylaxis and influence anaphylaxis severity in humans. We prospectively conducted a multicentric study of 86 patients with suspected anaphylaxis to neuromuscular-blocking agents (NMBAs) during general anesthesia and 86 matched controls. We found that concentrations of anti-NMBA IgG and markers of FcγR activation, PAF release, and neutrophil activation correlated with anaphylaxis severity. Neutrophils underwent degranulation and NETosis early after anaphylaxis onset, and plasma-purified anti-NMBA IgG triggered neutrophil activation ex vivo in the presence of NMBA. Neutrophil activation could also be observed in patients lacking evidence of classical IgE-dependent anaphylaxis. This study supports the existence of an IgG-neutrophil pathway in human NMBA-induced anaphylaxis, which may aggravate anaphylaxis in combination with the IgE pathway or underlie anaphylaxis in the absence of specific IgE. These results reconcile clinical and experimental data on the role of antibody classes in anaphylaxis and could inform diagnostic approaches to NMBA-induced acute hypersensitivity reactions.